MedTrace Logo

Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery

NCT02549768 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-10-12

No results posted yet for this study

Summary

Use of dexmedetomidine in pituitary tumor resection surgery as adjuvant drug and its relation to cortisol levels during postoperative period.

Conditions

  • Pituitary Neoplasms

Interventions

DRUG

Dexmedetomidine

At start of anesthesia, bolus of 1 mcg/kg of dexmedetomidine over 10 minutes and then infusion of 0.7 mcg/kg/h during surgery will be administered.

DRUG

Sodium Chloride 0.9%

Sodium chloride 0.9% with a pump programmed in same way as Dexmedetomidine pump

Sponsors & Collaborators

  • Pontificia Universidad Catolica de Chile

    lead OTHER

Principal Investigators

  • Juan C Pedemonte, MD · Physician

  • Pablo Villanueva, MD · Assisstant adjunct professor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-07-31
Completion
2017-08-31

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02549768 on ClinicalTrials.gov